F32CA081695 (EISCHEN, CHRISTINE M)Nov 10, 1999 NIH MEDIATORS OF MYC INDUCED MYELOID LEUKEMIA AND APOPTOSIS Role: Principal Investigator |
|
R01CA098139 (EISCHEN, CHRISTINE M)Jul 1, 2003 - Apr 30, 2009 NIH The Role of Mdm2 in Lymphoma Development Role: Principal Investigator |
|
R01CA117935 (EISCHEN, CHRISTINE M)Apr 9, 2007 - Feb 28, 2013 NIH p53-Independent Pathways in Mdm2-Mediated Transformation Role: Principal Investigator |
|
R01CA148950 (EISCHEN, CHRISTINE M.)Jan 1, 2011 - Jun 30, 2017 NIH Regulation of Myc-Mediated Tumorigenesis Role: Principal Investigator |
|
R01CA160432 (EISCHEN, CHRISTINE M.)Jul 26, 2012 - May 31, 2018 NIH SMARCAL1 function in replication stress and disease Role: Principal Investigator |
|
R01CA181204 (EISCHEN, CHRISTINE M.)Jul 18, 2014 - May 31, 2020 NIH Novel oncogenic functions of Mdm2 and Mdmx Role: Principal Investigator |
|
R01CA177786 (EISCHEN, CHRISTINE M.)Sep 15, 2014 - Aug 31, 2021 NIH Novel mechanisms of oncogenic transformation in lung cancer Role: Principal Investigator |
|
R21CA184352 (EISCHEN, CHRISTINE M.)Apr 7, 2015 - Mar 31, 2018 NIH Myc-induced pathways in B cell lymphoma initiation and survival Role: Principal Investigator |
|
R01CA226432 (EISCHEN, CHRISTINE M.)Dec 1, 2018 - Nov 30, 2024 NIH Replication stress in hematopoiesis and lymphomagenesis Role: Principal Investigator |
|
R01CA236853 (EISCHEN, CHRISTINE M.)Dec 1, 2019 - Nov 30, 2025 NIH BCLW in lymphoma survival and resistance to targeted BCL2 family therapies Role: Principal Investigator |
|
R01CA272645 (SALVINO, JOSEPH M)Sep 7, 2022 - Jul 31, 2027 NIH Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers Role: Co-Principal Investigator |
|
R01DE033025 (EISCHEN, CHRISTINE M.)Jul 1, 2023 - Apr 30, 2028 NIH Investigating a new vulnerability in oral squamous cell carcinoma Role: Principal Investigator |
|
R01CA279364 (POMERANTZ, RICHARD T)Dec 18, 2023 - Nov 30, 2028 NIH A Next-Generation Nucleoside Prodrug for Diffuse Large B-Cell Lymphoma Role: Co-Principal Investigator |